Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer
2011

Combining Smac Mimetics with Chemotherapy for Pancreatic Cancer

Sample size: 6 publication 10 minutes Evidence: moderate

Author Information

Author(s): Niranjan Awasthi, Amanda Kirane, Margaret A. Schwarz, Jason E. Toombs, Rolf A. Brekken, Roderich E. Schwarz

Primary Institution: The University of Texas Southwestern Medical Center

Hypothesis

Can the Smac mimetic JP1201 enhance the effectiveness of conventional chemotherapy agents in treating pancreatic ductal adenocarcinoma?

Conclusion

The combination of the Smac mimetic JP1201 with chemotherapy significantly improves tumor response and survival in pancreatic cancer models.

Supporting Evidence

  • JP and gemcitabine together caused a 30% decrease in tumor size in vivo.
  • Median survival was significantly improved in mice treated with JP + Gem compared to controls.
  • JP enhanced the effects of doxorubicin and docetaxel in PDAC cell lines.

Takeaway

This study shows that a special drug can help make chemotherapy work better against a tough type of cancer called pancreatic cancer.

Methodology

The study used cell viability assays, apoptosis detection, and in vivo tumor growth and survival studies in murine models.

Limitations

The study was conducted in preclinical models, which may not fully represent human responses.

Participant Demographics

The study involved SCID mice for in vivo experiments.

Statistical Information

P-Value

0.01

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2407-11-15

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication